Literature DB >> 25081657

Risk of cancer with combined oral contraceptive use among Iranian women.

Afasaneh Vaisy1, Shirin Lotfinejad, Faegh Zhian.   

Abstract

Oral contraceptive use is the most common type of contraception. More than 300 million women worldwide take oral contraceptives every day. However, there is a concern about the relationship with the incidence of cancer. This analytical retrospective study aimed to investigate the relationship between the incidence of cervical and breast cancers and oral contraceptive use in 128 Iranian patients with cervical cancer, 235 with breast cancer and equal numbers of controls. Data were collected through interviews with an organized set of questions. Details were also extracted from patient files. Data were analyzed using Student's t-test, chi-square and Fisher's exact tests, and Pearson's correlation analysis. The result revealed correlations between both cervical and breast cancers and history of contraceptive pills use. While cervical cancer significantly correlated with duration of use of pills, breast cancer had significant correlations with the type of oral contraceptive and age at first use. No significant relationships were found between the two types of cancer and age at discontinuation of oral contraceptives, patterns of use, and intervals from the last use. The use of oral contraceptives may triple the incidence of cervical cancer and doubles the incidence of breast cancer. Therefore, performing Pap smears every six months and breast cancer screening are warranted for long-term oral contraceptive users.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25081657     DOI: 10.7314/apjcp.2014.15.14.5517

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  Oral contraceptive use and kidney cancer risk among women: evidence from a meta-analysis.

Authors:  Huan Liu; Xing-Chun Wang; Guang-Hui Hu; Tian-Bao Huang; Yun-Fei Xu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

2.  A Clinical Decision Support System for Assessing the Risk of Cervical Cancer: Development and Evaluation Study.

Authors:  Nasrin Chekin; Haleh Ayatollahi; Mojgan Karimi Zarchi
Journal:  JMIR Med Inform       Date:  2022-06-22

3.  Assessing the Acceptability, Feasibility, and Effectiveness of a Tablet-Based Cervical Cancer Educational Intervention.

Authors:  M M Caster; A H Norris; C Butao; P Carr Reese; E Chemey; J Phuka; A N Turner
Journal:  J Cancer Educ       Date:  2017-03       Impact factor: 2.037

Review 4.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

Review 5.  Risk Factors of Synchronous Breast and Thyroid Cancer: a Controlled Multicenter Study and Review of the Literature.

Authors:  Stefanos Zervoudis; Georgios Iatrakis; Anisa Markja; Georgios Tsatsaris; Anastasia Bothou; Georg Fg von Tempelhoff; Mirsini Balafouta; Pana Tsikouras
Journal:  Mater Sociomed       Date:  2021-12

6.  Cervical cancer in Iran: integrative insights of epidemiological analysis.

Authors:  Zohre Momenimovahed; Hamid Salehiniya
Journal:  Biomedicine (Taipei)       Date:  2018-08-24

7.  Effect of age at first use of oral contraceptives on breast cancer risk: An updated meta-analysis.

Authors:  Li-Wei Ji; Chun-Xia Jing; Su-Lian Zhuang; Wei-Cheng Pan; Xing-Po Hu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

8.  Systematic screening for cervical cancer in Dakar region: prevalence and correlation with biological and socio-demographic parameters.

Authors:  Dominique Diouf; Gora Diop; Cheikh Ahmadou Tidian Diarra; Aminata Issa Ngom; Khadija Niane; Moussa Ndiaye; Sidy Ka; Oumar Faye; Ahmadou Dem
Journal:  Infect Agent Cancer       Date:  2020-04-22       Impact factor: 2.965

9.  Furin-responsive triterpenine-based liposomal complex enhances anticervical cancer therapy through size modulation.

Authors:  Yunyan Chen; Mengfei Guo; Ding Qu; Yuping Liu; Jian Guo; Yan Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.